Fact sheet: Polar Capital Biotechnology

Fund information
Fund name
Polar Capital Biotechnology I USD
Fund manager company
Polar Capital
Fund type
OEIC
Fund managers
  • David Pinnigersince 01/11/2013
Fund objective
The Fund aims to preserve capital and achieve long-term capital appreciation by investing throughout the biotechnology ecosystem, across geographies and market capitalisations.
Benchmark
  • NASDAQ Biotechnology
Investment style
Active,Growth
Investment method
Shares
Quick stats
1 Year return
18.6%
1 Year rank in sector
-
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.17%
Fund size
£117m (£46m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
194
Top in this sector
Fund name1 Year
BB Medtech20%
Pictet Health18.7%
Polar Capital Biotechnology18.6%
Variopartner SICAV MVGbMdtcF18.2%
Fidelity Gbl Health Care17.5%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA67.8%
    Switzerland8.2%
    Denmark6.3%
    UK4.6%
    Sweden3.7%
  • Biotechnology/Medical88.4%
    Pharmaceuticals6.7%
    Healthcare & Medical Products3.9%
    Money Market1.1%
  • US Equities67.7%
    Swiss Equities8.2%
    Danish Equities6.3%
    UK Equities4.6%
    Swedish Equities3.7%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund8%13%15.1%18.6%43.9%-
Sector3.1%1.6%0%4.4%21.8%103.9%
Rank within sector------
Quartile
Calendar performance
 YTD - 20172016201520142013
Fund8.9%-7.6%13%48.5%-
Sector4.3%-9.9%7.2%28.1%41%
Rank within sector-----
Quartile
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
5.96
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.46
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.47
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
26.21
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
13.21
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.59
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.82
Price movement
52 week high18.55
52 week low13.84
Current bid price-
Current offer price-
Current mid price18.39
Region
1USA67.8%
2Switzerland8.21%
3Denmark6.28%
4UK4.63%
5Sweden3.75%
6Ireland2.75%
7Germany1.67%
8Netherlands1.37%
9France1.29%
Industry sector
1Biotechnology/Medical88.4%
2Pharmaceuticals6.66%
3Healthcare & Medical Products3.85%
4Money Market1.09%
Asset type
1US Equities67.7%
2Swiss Equities8.2%
3Danish Equities6.3%
4UK Equities4.6%
5Swedish Equities3.7%
6Irish Equities2.8%
7German Equities1.7%
8Dutch Equities1.4%
9French Equities1.3%
Individual holdings
1ACTELION8.21%
2REGENERON PHARMACEUTICALS INC7.57%
3CELGENE CORP7.29%
4INCYTE CORP6.64%
5BIOGEN INC6.28%
6GENMAB AS4.5%
7TESARO INC4.41%
8GILEAD SCIENCES INC4.02%
9ALEXION PHARMACEUTICALS INC3.98%
Management
Fund manager group
Polar Capital
Fund manager company
Polar Capital
Fund type
OEIC
Fund objective
The Fund aims to preserve capital and achieve long-term capital appreciation by investing throughout the biotechnology ecosystem, across geographies and market capitalisations.
Benchmark
  • NASDAQ Biotechnology
Investment style
Active,Growth
Investment method
Shares
Fund managers
NameSinceBiography
David Pinniger01/11/2013David joined Polar Capital in August 2013 as a Fund Manager within the healthcare team. He has over 14 years’ investment experience in the healthcare sector. Prior to joining Polar Capital, for five years David was Portfolio Manager of the International Biotechnology Trust at SV Life Sciences. He also previously spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm’s venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector. David received a first class honours degree in human sciences from Oxford University in 1999 and is a CFA charterholder.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, IA Recognised, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Guernsey, Ireland, Italy, Jersey, Luxembourg, Netherlands, Norway, Offshore, Singapore, Sweden
Polar Capital Biotechnology I EUR
Initial charge5%
Annual charge1%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.17%
Total expense ratio (TER)1.35%
Bid price-
Offer price-
Mid price17.31
CurrencyEUR
Price updated13/01/2017
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeJTYE
Polar Capital Biotechnology I GBP
Initial charge5%
Annual charge1%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.17%
Total expense ratio (TER)1.35%
Bid price-
Offer price-
Mid price15.1
CurrencyGBP
Price updated13/01/2017
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeJTYF
Polar Capital Biotechnology I USD
Initial charge5%
Annual charge1%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.17%
Total expense ratio (TER)1.35%
Bid price-
Offer price-
Mid price18.39
CurrencyUSD
Price updated13/01/2017
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeJTYG
Polar Capital Biotechnology R EUR
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.67%
Total expense ratio (TER)1.85%
Bid price-
Offer price-
Mid price17.03
CurrencyEUR
Price updated13/01/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeJTYH
Polar Capital Biotechnology R GBP
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.67%
Total expense ratio (TER)1.85%
Bid price-
Offer price-
Mid price14.86
CurrencyGBP
Price updated13/01/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeJTYI
Polar Capital Biotechnology R USD
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.67%
Total expense ratio (TER)1.85%
Bid price-
Offer price-
Mid price18.1
CurrencyUSD
Price updated13/01/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeJTYJ
Polar Capital Biotechnology S EUR
Initial charge5%
Annual charge0.75%
Min single investment£10,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.92%
Total expense ratio (TER)1.25%
Bid price-
Offer price-
Mid price17.41
CurrencyEUR
Price updated13/01/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeJTYK
Polar Capital Biotechnology S GBP
Initial charge5%
Annual charge0.75%
Min single investment£10,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.92%
Total expense ratio (TER)1.25%
Bid price-
Offer price-
Mid price15.19
CurrencyGBP
Price updated13/01/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeJTYL
Polar Capital Biotechnology S USD
Initial charge5%
Annual charge0.75%
Min single investment£10,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.92%
Total expense ratio (TER)1.25%
Bid price-
Offer price-
Mid price18.5
CurrencyUSD
Price updated13/01/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeJTYM
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.